Macrolides as Biological Response Modifiers in Cystic Fibrosis and Bronchiectasis

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 6, 2003, Pages 737-747

  Bush, Andrew ^a,b   Rubin, Bruce K ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Adhesion molecule; Bronchiectasis; Cystic fibrosis; Cytokine; Diffuse panbronchiolitis; Macrolide; Neutrophils

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOCYTE ELASTASE; MACROLIDE; PHOSPHOLIPID; TRANSCRIPTION FACTOR; TROLEANDOMYCIN;

APOPTOSIS; ASTHMA; BIOFILM; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHUS HYPERREACTIVITY; CELL PROTECTION; CHEMOTAXIS; CYSTIC FIBROSIS; CYTOKINE RELEASE; DEGRANULATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME REPRESSION; FLOW KINETICS; HUMAN; IMMUNOMODULATION; MUCUS; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 0347182865     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815669     Document Type: Review

References (120)

1. Eigen H, Rosenstein B, Fitzsimmons S, Schidlow D. A multi-center study of alternate day prednisolone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-523
2. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997;77:124-130
3. Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997;156:1190-1196
4. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;322:848-854
5. Birrer P, McElvaney NG, Rudeberg C, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213
6. Bonfield TL, Konstan M, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is down-regulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995;13:257-261
7. Khan TZ, Wagener JS, Boat T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082
8. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and aetiology. Pediatr Pulmonol 1997;24:137-142
9. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204
10. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191
11. Scheid P, Kempster L, Griesenbach U, et al. Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. Eur Respir J 2001;17:27-35
12. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term, low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145-149
13. Fujii T, Kadota J, Kawakami K, et al. Long-term effects of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995;50:1246-1252
14. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement in survival of patients with diffuse panbronchiolitis treated with low dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832
15. Høiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994;49:531-532
16. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveolar lavage in diffuse panbronchiolitis. Chest 1994;106:1116-1123
17. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Invest Drugs 2000;1:169-172
18. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473
19. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209-229
20. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000;7:731-748
21. Mazzei T, Mini E, Novelli A, Perti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993;31(suppl C):S1-S9
22. Wu YJ. Highlights of semi-synthetic developments from erythromycin A. Curr Pharm Des 2000;6:181-223
23. Omura S, ed. Macrolide Antibiotics: Chemistry, Biology, and Practice. San Diego: Elsevier Science; 2002
24. Bearden DT, Rodvold KA. Penetration of macrolides into pulmonary sites of infection. Infect Med 1999;16:480-484
25. Miossec-Bartoli C, Pilatre L, Peyron P, et al. The new ketolide HMR3647 accumulates in the azurophil granule of human polymorhonuclear cells. Antimicrob Agents Chemother 1999;43:2457-2462
26. Vazifeh D, Abdelghaffar H, Labro MT. Cellular accumulation of the new ketolides RU64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob Agents Chemother 1997;41:2099-2107
27. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:828-833
28. Sakito O, Kadota J, Kohno S, et al. Interleukin-1, tumor necrosis factor-alpha, and interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism for macrolide therapy. Respiration 1996;63:42-48
29. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of 1L-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells in vitro. Eur Respir J 1995;8:1451-1457
30. Kawasaki S, Takizawa H, Ohtushi T, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998;42:1499-1502
31. Ashitani J, Mukae H, Nakazato M, et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in serum of patients with diffuse panbronchiolitis. Eur Respir J 1998;11:104-111
32. Mukae H, Kadota J, Ashitani J, et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997;112:1615-1621
33. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997;156:266-271
34. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-κβ and activator protein-1 in human bronchial epiuthelial cells. Biochem Biophys Res Commun 2000;267:124-128
35. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-κB, but not NFAT, through calcineurin-independent signalling in T-cells. Antimicrob Agents Chemother 1999;43:2678-2684
36. Abe S, Nakamura H, Inoue S, et al. Interleukin-8 gene repression by clarithromycin is mediated by activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60
37. Iino T, Toriyama M, Kudo K, Natori Y, You A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992;157(suppl):16-20
38. Schultz MJ, Speelman P, Zaat S, van Deventer SJ, van der Poll T. Erythromycin inhibits tumor necrosis alpha and interleukin-6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998;42:1605-1609
39. Kohyama T, Takizawa H, Kawasaki S, et al. Fourteen-membered macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 1999;43:907-911
40. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA. Erythromycin modulates eosinophil chemotactic Cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother 2001;45:401-406
41. Shimane T, Asano K, Suzuki M, Hisamitsu T, Suzaki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Mediators Inflamm 2001;10:323-332
42. Khan AA, Silfer TR, Araujo G, Remington JS. Effects of clarithromycin and azithromycin on production of cytokines by human monoocytes. Int J Antimicrob Agents 1999;11:121-132
43. Schultz MJ, Speelman P, Hack CE, et al. Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. J Antimicrob Chemother 2000;46:235-240
44. Lin HC, Wang CH, Liu CY, Yu CT, Kuo HP. Erythromycin inhibits beta2 integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med 2000;94:654-660
45. Matsuoka N, Eguchi K, Kawakami A, et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 1996;104:501-508
46. Mitsuyama T, Hidaka K, Furono T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997;114:111-115
47. Tamaoki J, Kondo M, Kohri K, et al. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999;163:2909-2915
48. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbachs-Mecarelli L. Neutrophils: molecules, functions, and pathophysiological aspects. Lab Invest 2000;80:617-653
49. Hojo M, Fujita I, Mamasaki M, Miyazaki S. Erythromycin does not affect neutrophil functions. Chest 1994;106:1116-1123
50. Torre D, Broggini M, Botta V, et al. In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes. J Chemother 1991;3:236-239
51. Labro MT, el Benna J, Babin-Chevaye C. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989;24:561-572
52. Villagrasa V, Berto L, Cortijo J, et al. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmacol 1997;29:605-609
53. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst in human polymorphonu-clear leucocytes. Antimicrob Agents Chemother 1990;34:863-870
54. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995;39:872-877
55. Brennan S, Cooper D, Sly PD. Directed neutrophil migration to 1L-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 2001;56:62-64
56. Andersen R, Fernandes AC, Eftychis HE. Studies on the ingestion of a single 500 mg oral dose of erythromycin stearate on leucocyte motility and transformation and on release in vitro of prostaglandin E2 by stimulated leucocytes. J Antimicrob Chemother 1984;14:41-50
57. Andersen R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989;159:966-973
58. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001;25:492-499
59. Jones A, Elphick H, Pettitt E, Everard ML, Evans GS. Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase. Eur Respir J 2002;19:1136-1141
60. Feldman C, Anderson R, Theron AJ, et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 1997;21:655-665
61. Feldman C, Anderson R, Theron A, et al. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J 1999;13:1022-1028
62. Okamoto K, Kishioka C, Kim JS, et al. Erythromycin inhibits mucin secretion in the inflamed trachea. Am J Respir Crit Care Med 1999;159:A35
63. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory infections. Antimicrob Agents Chemother 1995;39:1688-1690
64. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018-2023
65. Rubin BK. A superficial view of mucus and the cystic fibrosis defect. Pediatr Pulmonol 1992;13:4-5
66. Shibuya Y, Wills PJ, Cole PJ. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respiration 2001;68:615-619
67. Miyatake H, Taki F, Taniguchi H, et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991;99:670-673
68. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 1998;12:57-63
69. Tamaoki J, Tagaya E, Sakai A, Konno K. Effect of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995;95:853-859
70. Yatsunami J, Fukuno Y, Nagata M, et al. Antiangiogenic and antitumor effects of 14-membered macrolides on mouse B16 melanoma cells. Clin Exp Metastasis 1999;17:361-367
71. Yatsunami J, Tsuruta N, Hara N, Hayashi S. Inhibition of tumour angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998;131:137-143
72. Oyama T, Sakuta T, Matsushita K, et al. Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. J Periodontol 2000;71:1546-1553
73. Kitadai Y, Takahashi Y, Haruma K, et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 1999;81:647-653
74. Yatsunami J, Tsuruta N, Ogata K, et al. Interleukin-8 participates in angiogenesis in non-small cell but not small cell carcinoma of the lung. Cancer Lett 1998;120:101-108
75. Nonaka M, Pawankar R, Tomiyama S, Yagi T. A macrolide antibiotic, roxithromycin, inhibits the growth of nasal polyp fibroblasts. Am J Rhinol 1999;13:267-272
76. Davies J, Stern M, Dewar A, et al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol 1997;16:657-663
77. Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-67
78. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-236
79. Baumann U, Fischer JJ, Gudowius P, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001;29:7-11
80. Tsang KW, Ng P, Ho PL, et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J 2003;21:401-406
81. Yamasaki T. Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium: the effect of antimicrobial agents. J Jpn Assoc Infect Dis 1990;64:575-583
82. Kawamura-Sato K, Iinuma Y, Hasegagwa T, et al. Effect of subinhibitory concentrations of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000;44:2869-2872
83. Kawamura-Sato K, Iinuma Y, Hasegagwa T, Yamashino T, Ohta M. Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. J Infect Chemother 2001;7:51-54
84. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependant bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-2275
85. Kishioka C, Okamoto K, Hassett DJ, de Mello D, Rubin BK. Pseudomonas aeruginosa alginate is a potent secretagogue in the isolated ferret trachea. Pediatr Pulmonol 1999;27:174-179
86. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99:265-305
87. Mizukane R, Hirataka Y, Kaku M, et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:528-533
88. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46:1105-1107
89. Torrens TK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998;53:182-185
90. Wallace RJ Jr, Zhang Y, Brown-Elliot BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002;186:266-273
91. McKlendin K, Stark P. Mycobacterium avium intracellulare complex as a cause of bronchiectasis. Semin Respir Infect 2001;16:85-87
92. Piedmonte G, Wolford ET, Fordham LA, Leigh MW, Wood RE. Mediastinal lymphadenopathy caused by Mycobacterium avium-intracellulare complex in a child with normal immunity. Pediatr Pulmonol 1997;24:287-291
93. Tsang KW, Lam S-K, Lam W-K, et al. High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med 1998;158:1047-1051
94. Lallemand JY, Stoven V, Annereau JP, et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis [abstract]. Lancet 1997;350:711-712
95. Sermet-Gaudelus I, Kessler R, Stoven V, et al. Dramatic improvement of cystic fibrosis during and after antitumurous chemotherapy: a report of three cases. Pediatr Pulmonol 1998;17(suppl):219-220
96. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vivo induction of liver p-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995;133:269-276
97. Altschuler EL. Azithromycin, the multidrug resistant protein, and cystic fibrosis [letter]. Lancet 1998;351:1286
98. Kanoh S, Kondo M, Tamaoki J, et al. Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. Am J Physiol (Lung Cell Molec Physiol) 1999;276:L891-L899
99. Zhao D-M, Xue H-H, Chida K, et al. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol 2000;278:L276-L336
100. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine epithelial cells. Eur Respir J 1992;5:234-238
101. Nakanishi N, Ueda N, Kitade M, Moritaka T. A case of cystic fibrosis in a Japanese student. Jpn J Thoracic Dis 1995;33:771-774
102. Ordonez CL, Stulbarg M, Grundland H, et al. Effect of clarithromycin on airway obstruction and sputum neutrophilia in patients with cystic fibrosis. Am J Respir Crit Care Med 1999;159:A680
103. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis [research letter]. Lancet 1998;351:420
104. Wolter J, Seeney S, Bell S, et al. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised controlled trial. Thorax 2002;57:212-216
105. Equi A, Balfour-Lynn I, Bush A, Rosenthal M. Long-term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002;360:978-984
106. Ripoll L, Reinert P, Pepin LF, Lagrange PH. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996;37:987-991
107. Saiman L, Marshall BC, Mayer-Hamblett N. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756
108. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushet HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32:29-37
109. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2000;(3): CD002203
110. Seppala H, Klauka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-446
111. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002;122:213-218
112. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997;10:994-999
113. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997;10:994-999
114. de Benedictis FM, Bush A. Hypothesis paper: rhinosinusitis and asthma - epiphenomenon or causal association? Chest 1999;115:550-556
115. Rhee C-S, Majima Y, Arima S, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000;109:484-487
116. MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001;18:75-82
117. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000;14:143-148
118. Suzuki H, Shimomura A, Ikeda K, et al. Inhibitory effect of macrolides on interleukin-8 secretion from cultured nasal epithelial cells. Laryngoscope 1997;107:1661-1666
119. Katz L, Doniado S. Polyketide synthesis: prospects for hybrid antibiotics. Annu Rev Microbiol 1993;47:875-912
120. Tsoi CJ, Khosla C. Combinatorial biosynthesis of "unnatural" natural products: the polyketide example. Chem Biol 1995;2:355-362